2006
Expanded HIV screening in the United States: effect on clinical outcomes, HIV transmission, and costs.
Paltiel AD, Walensky RP, Schackman BR, Seage GR, Mercincavage LM, Weinstein MC, Freedberg KA. Expanded HIV screening in the United States: effect on clinical outcomes, HIV transmission, and costs. Annals Of Internal Medicine 2006, 145: 797-806. PMID: 17146064, DOI: 10.7326/0003-4819-145-11-200612050-00004.Peer-Reviewed Original ResearchConceptsCost-effectiveness ratioDollars/QALYHIV prevalenceAnnual incidenceHIV infectionRoutine HIVAntiretroviral therapyIncremental cost-effectiveness ratioModerate HIV prevalenceUndetected HIV infectionVoluntary HIV screeningUndiagnosed HIV infectionRapid HIV testingHIV patient careHIV transmission riskOne-time screeningQuality-adjusted survivalLifetime medical costsServices Utilization SurveySecondary transmissionBase-case analysisCost-effectiveness analysisHIV screeningObservational cohortHIV testing
2002
State AIDS Drug Assistance Programs
Johri M, Paltiel A, Goldie S, Freedberg K. State AIDS Drug Assistance Programs. Medical Care 2002, 40: 429-441. PMID: 11961477, DOI: 10.1097/00005650-200205000-00008.Peer-Reviewed Original ResearchMeSH KeywordsAcquired Immunodeficiency SyndromeAnti-HIV AgentsCD4 Lymphocyte CountCost of IllnessCost-Benefit AnalysisDirect Service CostsDisease ProgressionEfficiency, OrganizationalEligibility DeterminationHealth Services AccessibilityHumansInsurance CoverageInsurance, Pharmaceutical ServicesLife ExpectancyMedical AssistanceModels, EconometricOrganizational InnovationQuality-Adjusted Life YearsState Health PlansUnited StatesConceptsQuality-adjusted life yearsLifetime direct medical costsLife yearsDirect medical costsDrug Assistance ProgramsAssistance programsState-transition simulation modelQuality-adjusted life expectancyADAP programEconomic performanceLife expectancyMedical costsCost-effective useLifetime costsCost dataServices Utilization SurveyState policyAIDS CostState AIDSCoverage variesComprehensive policyUtilization SurveyPolicyCare resourcesPessimistic assumptions
2001
The Cost Effectiveness of Combination Antiretroviral Therapy for HIV Disease
Freedberg K, Losina E, Weinstein M, Paltiel A, Cohen C, Seage G, Craven D, Zhang H, Kimmel A, Goldie S. The Cost Effectiveness of Combination Antiretroviral Therapy for HIV Disease. New England Journal Of Medicine 2001, 344: 824-831. PMID: 11248160, DOI: 10.1056/nejm200103153441108.Peer-Reviewed Original ResearchMeSH KeywordsAIDS-Related Opportunistic InfectionsAnti-HIV AgentsCD4 Lymphocyte CountComputer SimulationCost-Benefit AnalysisDirect Service CostsDisease ProgressionDrug CostsDrug Therapy, CombinationHealth Care CostsHIV InfectionsHumansLife ExpectancyModels, BiologicalQuality-Adjusted Life YearsRNA, ViralUnited StatesValue of LifeConceptsQuality-adjusted yearThree-drug therapyCombination antiretroviral therapyCD4 cell countQuality of lifeAntiretroviral therapyHIV diseaseClinical benefitDrug costsLife expectancyCell countInitial CD4 cell countThree-drug antiretroviral regimensHuman immunodeficiency virus (HIV) infectionHIV RNA levelsPerson lifetime costsImmunodeficiency virus infectionMajor clinical trialsDirect medical costsStandard of careProgression of diseaseLifetime direct medical costsCost-effectiveness ratioServices Utilization SurveyCost effectiveness
1998
The Cost-effectiveness of Preventing AIDS-Related Opportunistic Infections
Freedberg KA, Scharfstein JA, Seage GR, Losina E, Weinstein MC, Craven DE, Paltiel AD. The Cost-effectiveness of Preventing AIDS-Related Opportunistic Infections. JAMA 1998, 279: 130-136. PMID: 9440663, DOI: 10.1001/jama.279.2.130.Peer-Reviewed Original ResearchMeSH KeywordsAcquired Immunodeficiency SyndromeAIDS-Related Opportunistic InfectionsAnti-Infective AgentsCD4 Lymphocyte CountChemopreventionCost-Benefit AnalysisCytomegalovirus InfectionsData CollectionHealth Care CostsHumansLife ExpectancyMarkov ChainsModels, TheoreticalMycobacterium avium-intracellulare InfectionMycosesPneumonia, PneumocystisQuality-Adjusted Life YearsRisk FactorsToxoplasmosisUnited StatesConceptsPneumocystis carinii pneumoniaCD4 cell countQuality-adjusted life expectancyOpportunistic infectionsCell countLife expectancyAdvanced human immunodeficiency virus diseaseAverage total lifetime costsHuman immunodeficiency virus (HIV) diseaseMycobacterium avium complex infectionMulticenter AIDS Cohort StudyIncremental cost-effectiveness ratioHIV patient careCost of prophylaxisCost-effective prophylaxisDirect medical costsAIDS Cohort StudyLifetime direct medical costsLong-term survivalCost-effectiveness ratioServices Utilization SurveyMarkov simulation modelTotal lifetime costsCytomegalovirus diseasePreventing AIDS